Analysis of the duration of and reasons for changing the first combination of antiretroviral therapy

M.T. Martín , M. Rovira , M. Massanes , E. del Cacho , E. Carcelero , M. Tuset , C. Codina , J.M. Miro , J.M. Gatell , J. Ribas
{"title":"Analysis of the duration of and reasons for changing the first combination of antiretroviral therapy","authors":"M.T. Martín ,&nbsp;M. Rovira ,&nbsp;M. Massanes ,&nbsp;E. del Cacho ,&nbsp;E. Carcelero ,&nbsp;M. Tuset ,&nbsp;C. Codina ,&nbsp;J.M. Miro ,&nbsp;J.M. Gatell ,&nbsp;J. Ribas","doi":"10.1016/S2173-5085(10)70016-2","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>To determine the duration of and reasons behind changing the various combinations of drugs used for the initiation of antiretroviral treatment in naïıve patients.</p></div><div><h3>Methods</h3><p>A retrospective observational study that included all patients with HIV infection who started antiretroviral therapy in a high-tech university reference hospital during the period from 1 January 2003 and 31 December 2005. Patients were followed until 31 December 2008. To estimate the cumulative probability of discontinuation the Kaplan- Meier method was used.</p></div><div><h3>Results</h3><p>A total of 441 patients were included. The average duration of the first treatment was 384 (interquartile interval 84–1290) days. The regimen based on non-nucleoside reverse transcriptase inhibitors and those that included as nucleosides abacavir or tenofovir in combination with lamivudine or emtricitabine showed a significantly longer duration than the rest. The main reasons for termination were the side effects, although in a lesser percentage than that obtained in previous studies. No associations were found between the rest of the characteristics of the patients or of the treatment and the risk of termination.</p></div><div><h3>Discussion</h3><p>Although the duration of the first antiretroviral treatment remains short, currently fewer changes are made due to side effects and due to loss to follow-up. The reasons may be better tolerance and less complexity. However, more studies are needed to determine the benefits of one regimen or another, and to be able to generalise the results.</p></div>","PeriodicalId":100521,"journal":{"name":"Farmacia Hospitalaria (English Edition)","volume":"34 5","pages":"Pages 224-230"},"PeriodicalIF":0.0000,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S2173-5085(10)70016-2","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Farmacia Hospitalaria (English Edition)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2173508510700162","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective

To determine the duration of and reasons behind changing the various combinations of drugs used for the initiation of antiretroviral treatment in naïıve patients.

Methods

A retrospective observational study that included all patients with HIV infection who started antiretroviral therapy in a high-tech university reference hospital during the period from 1 January 2003 and 31 December 2005. Patients were followed until 31 December 2008. To estimate the cumulative probability of discontinuation the Kaplan- Meier method was used.

Results

A total of 441 patients were included. The average duration of the first treatment was 384 (interquartile interval 84–1290) days. The regimen based on non-nucleoside reverse transcriptase inhibitors and those that included as nucleosides abacavir or tenofovir in combination with lamivudine or emtricitabine showed a significantly longer duration than the rest. The main reasons for termination were the side effects, although in a lesser percentage than that obtained in previous studies. No associations were found between the rest of the characteristics of the patients or of the treatment and the risk of termination.

Discussion

Although the duration of the first antiretroviral treatment remains short, currently fewer changes are made due to side effects and due to loss to follow-up. The reasons may be better tolerance and less complexity. However, more studies are needed to determine the benefits of one regimen or another, and to be able to generalise the results.

首次联合抗逆转录病毒治疗的持续时间及改变原因分析
目的确定naïıve患者开始抗逆转录病毒治疗时改变各种药物组合的持续时间和原因。方法回顾性观察研究,纳入2003年1月1日至2005年12月31日在某高新技术大学参考医院接受抗逆转录病毒治疗的所有HIV感染者。患者随访至2008年12月31日。使用Kaplan- Meier方法估计终止的累积概率。结果共纳入441例患者。第一次治疗的平均持续时间为384天(四分位数间隔84-1290)。以非核苷类逆转录酶抑制剂为基础的方案和核苷类包括阿巴卡韦或替诺福韦与拉米夫定或恩曲他滨联合的方案的持续时间明显长于其他方案。终止治疗的主要原因是副作用,尽管这一比例低于以往的研究。未发现患者的其他特征或治疗与终止风险之间存在关联。尽管第一次抗逆转录病毒治疗的持续时间仍然很短,但目前由于副作用和随访损失而进行的改变较少。原因可能是更好的容忍度和更少的复杂性。然而,需要更多的研究来确定一种方案或另一种方案的益处,并能够推广结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信